Acute Lung Injury Market Size Projected To Reach 3.09 Billion By 2034 With A Cagr Of 4.4%

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Projected Growth of the Acute Lung Injury Market?
In recent years, there has been a consistent expansion in the acute lung injury market size. The market is predicted to rise from $2.48 billion in 2024 to $2.60 billion in 2025, attaining a compound annual growth rate (CAGR) of 4.7%.Factors conducive to growth during the historic period include awareness campaigns, a rise in ICU admissions, the prevalence of smoking and air pollution, an increase in hospital-acquired infections, and attempts to reduce mortality rates.

It is anticipated that the market size for acute lung injury will experience continued growth over the coming years. Forecasts predict it expanding to $3.09 billion by 2029 with a compound annual growth rate (CAGR) of 4.4%.This projected growth during this period can be credited to factors such as advances in biologics and gene therapies, government funding and grants, advancements in precision and regenerative medicine, stem cell therapies, and reformations in global health policies. The forecast period is also expected to see significant trends such as the creation of biologic drugs, the utilization of wearable and remote monitoring devices, the use of inhalation-based therapies, developments in CRISPR and gene editing technologies, and the introduction of biosensors for immediate analysis.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20704

What Are the Different Acute Lung Injury Market Segments?
The acute lung injury market covered in this report is segmented -

1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp

What Are the Primary Drivers Shaping the Acute Lung Injury Market?
The increased incidence of respiratory conditions is predicted to fuel the expansion of the acute lung injury market. Respiratory diseases encompass a variety of disorders that impact the lungs and other components of the respiratory system, causing breathing difficulties and lung dysfunction. The heightened occurrence of these diseases could be attributed to growing air pollution, smoking habits, sedentary lifestyles, older demographics, and viral infections' consequences. Infections such as pneumonia induce acute lung injury by causing severe inflammation and alveoli damage, leading to compromised gas exchange and respiratory distress. For example, the Australian Bureau of Statistics reported in September 2023 that the mortality rate from influenza and pneumonia in Australia increased significantly by about 33.54%, from 31.9 per 100,000 individuals in 2021 to 42.6 per 100,000 individuals in 2022. Thus, the escalating incidence of respiratory diseases is propelling the growth of the acute lung injury market.

Which Companies Are Leading in the Acute Lung Injury Market?
Major companies operating in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., MediciNova Inc.

What Are the Major Trends Shaping the Acellular Dermal Matrices Market?
Leading businesses in the acute lung injury market, such as peptide treatments, are innovating and developing unique treatment methodologies to maintain their market dominance. Peptide treatment involves utilizing short amino acid chains or peptides for therapeutic purposes in treating health conditions. For example, in November 2022, Aviptadil was launched by Zuventus Healthcare Ltd., an Indian healthcare company aiming to treat acute respiratory distress syndrome (ARDS). This treatment option provides multiple distinct benefits, including an efficient lung protection mechanism and anti-inflammatory effects that suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha. The treatment also has a potent vasodilatory property which is 50 times stronger than prostacyclin and immunomodulatory action that controls immune reactions in the lungs. Evidence has shown that Aviptadil is clinically effective in enhancing outcomes for severe viral-related ARDS patients.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report

What Are the Top Revenue-Generating Geographies in the Acute Lung Injury Market?
North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Lung Injury Market?
2. What is the CAGR expected in the Acute Lung Injury Market?
3. What Are the Key Innovations Transforming the Acute Lung Injury Industry?
4. Which Region Is Leading the Acute Lung Injury Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.